Novartis walks away from 3rd Zolgensma plant just a year after leasing it as it pivots resources to next-gen pipeline
When Novartis leased a facility in Longmont, CO just a year ago from AstraZeneca, it had big plans to ramp up manufacturing for gene therapy Zolgensma. That was just on the heels of the AveXis data scandal, and now, with Zolgensma sales flagging, Novartis has decided to walk away.
Novartis will depart the Longmont site by July at the latest, the company said in a statement, which will leave 400 employees across the facility without jobs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.